Moderna reported Q3 2026 revenue of $1.31 billion, up 29% year over year and well above analysts’ estimates of roughly $885–$890 million.
The main driver was stronger COVID-19 vaccine sales in international markets, alongside deliveries under long-term government partnerships. Revenue was $780 million in the U.S. and $533 million internationally.
The company swung to a $162 million profit from a $200 million loss a year earlier, reporting earnings of 38 cents per share against forecasts for a loss.
Moderna raised its 2026 revenue-growth outlook to 15%–25%, from its prior forecast of growth of up to 10%.
Sources:
Moderna (MRNA) earnings Q3 2026
Moderna Lifts Outlook, Swings to 3Q Profit
Moderna's COVID vaccine carries stellar Q3 revenue beat
sec-gov-archives-edgar-data-1682852-000168285226000194-exhibit9912026q3pressrelea-htm
What Moderna (MRNA) Said on Its Q3 Earnings Call
Moderna, Inc. Q3 2026 Earnings Call Summary
Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and ...
Moderna lifts annual revenue forecast on strong COVID vaccine demand ...
Moderna shares surge 10% on earnings beat and raised revenue outlook
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises
Moderna Considers Next Steps for Intismeran, Raises Growth Estimates
Earnings live updates: Moderna's COVID vaccine sales drive revenue growth, raised outlook
Moderna Returns To Q3 Profit; Raises FY26 Outlook On Vaccine Sales And Pipeline Progress
Moderna Q3 Beats Estimates, Raises Full-Year Revenue Outlook Sharply